Novartis Presents Additional Data on Breast Cancer Candidate - Zacks.com

Novartis Presents Additional Data on Breast Cancer Candidate  Zacks.comNovartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer.